Download presentation
Presentation is loading. Please wait.
1
Top Tips in Evidence-Based Care for HFrEF
3
Typical Patient With HFrEF
4
Key Therapies in HFrEF: How Do They Work?
5
2016 ESC HF Guidelines: Next...Add an MRA and ARNI
6
Principles for Successful Treatment for HF
7
Starting and Titrating Drug Therapies in HFrEF
8
ESC 2016 Guidelines: Classifications of HF
9
CHARM: Candesartan Reduced CV Death + Time to First HF Hospitalization in HFrEF and HFmrEF Categories
10
Benefit of ARNI in HFrEF: Primary Composite Endpoint -- CV Death and First HF Hospitalization
11
Additional Key Points: PARADIGM-HF
12
PARADIGM-HF: Benefit of ARNI in HFrEF to Reduce Time to First Hospitalization for HF Was Seen Very Early
13
Managing Diabetes in the Presence of HFrEF
14
SGLT2 Inhibitors: Use in Diabetes and HF
15
Ongoing Trials With SGLT2 Inhibitors in Patients With Diabetes and HF
16
Questions to Ponder and Points of Clarification: SGLT2 Inhibitors in HF
17
Altered Patient Scenario: Tachycardia in HFrEF
18
SHIFT Trial: Increased Risk of CV Death and HF Hospitalization With Increased Heart Rate in SR in HF
19
AF and HF
20
Heart Rate as a Predictor of Outcome in HF
21
Anticoagulation and AF in HF
22
Management of HF in the Inpatient Setting
23
PIONEER HF: Safety of ARNI -- Including ACE Inhibitor and ARB-Naive Patients With HFrEF
24
PIONEER HF: Exploratory Clinical Endpoints
25
Clarification of Terms -- What Do We Mean?
26
Conclusions
27
Abbreviations
28
Abbreviations (cont)
29
Abbreviations (cont)
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.